Skip to main content

Mecasermin Disease Interactions

There are 4 disease interactions with mecasermin.

Moderate

Mecasermin (applies to mecasermin) diabetics

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Mecasermin has insulin-like hypoglycemic effects, therefore, care should be taken when prescribing this agent to diabetic patients. It is recommended to monitor blood glucose levels in these patients until a well-tolerated dose is established and subsequently as medically indicated.

References

  1. (2005) "Product Information. Increlex (mecasermin)." Tercica Inc
Moderate

Mecasermin (applies to mecasermin) lymphoid tissue hypertrophy

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Sleep Apnea

Lymphoid tissue (e.g., tonsillar and adenoidal) hypertrophy associated with complications such as snoring, sleep apnea, and chronic middle-ear effusions have been reported with the use of mecasermin. Patients presenting these complications should be periodically examined to rule-out the occurrence of lymphoid tissue hypertrophy. Care should be taken when prescribing mecasermin to these patients.

References

  1. (2005) "Product Information. Increlex (mecasermin)." Tercica Inc
Moderate

Mecasermin (applies to mecasermin) scoliosis

Moderate Potential Hazard, Moderate plausibility.

Because mecasermin increases growth rate, patients who experience rapid growth should be closely monitored for any onset of a limp or complaints of hip or knee pain. Patients with a history of scoliosis who are treated with mecasermin should be monitored for progression of scoliosis. Care should be taken when prescribing this agent to patients with a history of scoliosis.

References

  1. (2005) "Product Information. Increlex (mecasermin)." Tercica Inc
Moderate

Mecasermin (applies to mecasermin) visual complications

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance

Intracranial hypertension with papilledema, visual changes, headache, nausea and/or vomiting have occurred in patients treated with mecasermin. Ophthalmologic examination is recommended at the initiation and periodically during the course of mecasermin therapy. Assessment is recommended prior to prescribing this agent to patients with ocular complications.

References

  1. (2005) "Product Information. Increlex (mecasermin)." Tercica Inc

Mecasermin drug interactions

There are 24 drug interactions with mecasermin.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer